Another combination worth exploring will be that of selective CDK2 plus novel CDK4 inhibitors (i.e., CDK6-sparing), with the rationale of reducing toxicity while exploiting the primary CDK4 dependency of many luminal breast cancers (e.g., NCT05262400; refs. 4, 19, 45). This evidence concerns the gene CDK2 and breast carcinoma.